

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.



Link-Asia International MedTech Group Limited

環亞國際醫療科技集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

FURTHER DELAY IN DESPATCH OF CIRCULAR

Reference is made to (i) the announcements of Link-Asia International MedTech Group Limited (the “**Company**”) dated 18 January 2022 in relation to the Assignment of Agency Agreement involving the issue of Consideration Shares under Specific Mandate and (ii) the announcement of the Company dated 9 February 2022, 4 March 2022, 25 March 2022 and 19 April 2022 in relation to the delay in despatch of circular (collectively the “**Announcements**”). Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

As disclosed in the Announcements, a circular (the “**Circular**”) containing, among other information, (i) details of the Assignment; (ii) details of the Specific Mandate; and (iii) a notice convening the EGM together with a form of proxy for use at the EGM was expected to be despatched to the Shareholders on or before 5 May 2022. As additional time is required for the Company to finalise certain information to be included in the Circular, the Company expects that the date of despatch of the Circular will be postponed to a date falling on or before 13 May 2022.

By order of the Board

Link-Asia International MedTech Group Limited

Lin Dailian

Chairman and executive Director

Hong Kong, 5 May 2022

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Duan Chuanhong and Ms. Lin Xiaoshan as executive Directors; Mr. Li Huiwu, Mr. Yang Weidong and Mr. Chak Chi Shing as independent non-executive Directors.